ZoladexOrdering.com

Welcome to ZOLADEX Ordering - We are pleased to offer health care professionals the ability to order ZOLADEX online along with educational and support materials.

At ZOLADEXordering.com, you can find the following services:

Order ZOLADEX 3.6 mg 1-month Depot and 10.8 mg 3-month Depot
Download materials for your patients
Order printed materials for your patients

Logon to ZOLADEX
Ordering

Prescribing Information

Print This Page

Send to a Colleague

Change Text Size - A A A

Don't have time for another phone call? Online ordering is 3 clicks away. Click here for the shipping schedule.

Prostate cancer information for patients and health care professionals. PROSTATEinfo.com

Indications and Important Safety Information

ZOLADEX 3.6 mg depot and 10.8 mg depot are indicated in the palliative treatment of advanced carcinoma of the prostate.

ZOLADEX 3.6 mg depot and 10.8 mg depot are also indicated for use in combination with flutamide for the management of locally advanced Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with the combination should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.

ZOLADEX, like other luteinizing hormone-releasing hormone analogs (LHRH-As), may cause a transient rise in testosterone. When used alone, there may be a temporary worsening of prostate cancer symptoms at the start of therapy.
Development of diabetes has been reported in men receiving LHRH-As like ZOLADEX. Consider monitoring blood glucose in patients receiving ZOLADEX.
The most common adverse events (incidence > 5%) in advanced carcinoma of the prostate clinical trials were: for ZOLADEX 3.6 mg depot—hot flashes (62%), sexual dysfunction (21%), decreased erections (18%), lower urinary tract symptoms (13%), lethargy (8%), pain (worsened in the first 30 days) (8%), edema (7%), upper respiratory infection (7%), rash (6%), and sweating (6%); for ZOLADEX 10.8 mg depot—hot flashes (64%), pain (general) (14%), gynecomastia (8%), pelvic pain (6%), and bone pain (6%).
In the locally advanced carcinoma of the prostate clinical trial, additional adverse event data were collected for the combination therapy with radiation group during both the hormonal treatment and hormonal treatment plus radiation phases of this study. Adverse experiences (incidence > 5%) in both phases of this study were hot flashes (46%), diarrhea (40%), nausea (9%), and skin rash (8%).

Click here for ZOLADEX^® (goserelin acetate implant) 3.6 mg 1-month Depot Full Prescribing Information
Click here for ZOLADEX^® (goserelin acetate implant) 10.8 mg 3-month Depot Full Prescribing Information

ZOLADEX is a registered trademark of the AstraZeneca group of companies.

This information is intended for US health care professionals only.

US Corporate Site | Site Map | Contact Us | Privacy Statement | Legal Terms and Conditions